Browse the evidence

The percentage of patients who had a glycated hemoglobin level of 6.5% or less was significantly higher in the cagrilintide-semaglutide group compared to the placebo group.

This treatment may significantly improve glycemic control in patients with type 2 diabetes.

Resistance training (RT) can elicit similar health benefits to aerobic training (AT).

Practitioners should consider incorporating RT alongside AT for optimal health benefits.

Regular resistance training is associated with a lower mortality risk.

Encouraging regular RT can be a strategy to reduce mortality risk.

The proportion of lean mass relative to total body mass increased, suggesting a positive overall outcome.

The increase in lean mass proportion may indicate that semaglutide can help maintain muscle relative to fat loss.

The low-carbohydrate diet intervention group had a significantly greater 6-month reduction in HbA1c of -0.23% compared to the usual diet group.

A low-carbohydrate diet may be effective in reducing HbA1c levels in individuals with prediabetes or untreated diabetes.

The low-carbohydrate diet intervention group experienced a significant reduction in fasting plasma glucose of -10.3 mg/dL.

Implementing a low-carbohydrate diet may help lower fasting plasma glucose levels in individuals with prediabetes or untreated diabetes.

Weight loss and fat mass loss through lifestyle and pharmacologic interventions improve metabolic and inflammatory markers, suggesting a link to decreased breast cancer risk.

Practitioners should encourage weight loss and fat mass reduction as strategies to lower breast cancer risk.

bMVPA performed in the afternoon is associated with a greater reduction in HbA1c compared to inactive individuals, with a reduction of -0.22%.

Practitioners may consider recommending afternoon physical activity to improve glycemic control in patients with type 2 diabetes.

Therapeutic strategies that promote significant and sustained weight loss (~10% of total body weight) are among the most efficient for treating NASH and T2D.

Weight loss interventions should be prioritized in managing NASH and T2D.

Limiting saturated fatty acids intake to <10% of total caloric intake in obesity and <7% in hypercholesterolemia is recommended.

Practitioners should advise patients to limit saturated fat intake according to these guidelines.

Daily dietary fiber intake should reach a level of 25-40 g.

Encourage patients to increase their dietary fiber intake to meet these levels.

INV-202 exhibited significant reductions in waist circumference and BMI (P ≤ 0.03).

INV-202 may help reduce waist circumference and BMI in this population.

Clinical data supporting the use of various FDA-approved medications for weight loss are presented.

Practitioners can rely on clinical data when prescribing FDA-approved weight loss medications.

For trials with a mean BMI ≥35, LDL cholesterol decreased by 7 mg/dL on a low-carbohydrate diet.

Practitioners should note that low-carbohydrate diets may lower LDL cholesterol in individuals with high BMI.

High total protein intake is associated with low CVD morbidity (RR 0.88, 95% CI 0.82-0.94).

Encouraging higher protein intake may reduce the risk of cardiovascular disease.

Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide.

Practitioners should emphasize lifestyle changes in addition to pharmacotherapy for optimal management.

Tai Chi exercise therapy significantly decreases fasting blood glucose (FBG) by an average of 0.79 mmol/L in patients with type 2 diabetes mellitus (T2DM).

Incorporating Tai Chi into exercise prescriptions may help lower blood glucose levels in T2DM patients.

Tai Chi exercise therapy significantly decreases glycated hemoglobin (HbA1c) by an average of 1.10% in patients with T2DM.

Tai Chi may be an effective intervention for improving long-term glucose control in T2DM patients.

Personalized nutrition informed by genetic and metabolic profiling is a promising approach to tailor recovery strategies.

Tailoring recovery nutrition based on individual profiles can enhance recovery outcomes.

Exercise is a key component of nonalcoholic fatty liver disease (NAFLD) treatment.

Practitioners should incorporate exercise into treatment plans for NAFLD.

The effectiveness of exercise in improving NAFLD is influenced by exercise type, intensity, and volume.

Exercise programs should consider these factors to optimize treatment outcomes.

Tirzepatide exhibited favorable effects on glycemic control, with reductions in HbA1c levels ranging from 20.4 mmol/mol with the 5 mg dose to 28.2 mmol/mol with the 15 mg dose.

Tirzepatide may improve glycemic control in patients with T2DM.

Tirzepatide resulted in mean waist circumference reductions ranging from 4.3 to 9.8 cm across subgroups.

Tirzepatide is effective in reducing waist circumference in East Asian individuals with type 2 diabetes.

Retatrutide and orforglipron are effective in weight loss and improving metabolic parameters associated with obesity.

These drugs may be considered as therapeutic options for obesity management.